Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192075
Status:
COMPLETED
Last Update Posted:
2011-02-07
First Post:
2005-09-12
Brief Title:
A Randomized Trial of Avastin Gemcitabine 5-Fluorouracil 5FUFolinic Acid Versus Avastin Oxaliplatin 5FUFolinic Acid in Metastatic Colorectal Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Multicenter Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FUFolinic Acid A FFG vs Avastin Plus Oxaliplatin Plus 5FUFolinic Acid A FOLFOX 4 as Therapy for Patients With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to describe the tumor response rates for the two regimens being studied and to determine how long patients live after receiving the treatment how long patients are without return of their disease after they receive treatment and how long the response they get from the treatment lasts The amount and type of side effectstoxicities of each regimen will also be evaluated The regimen including Oxaliplatin 5FUFolinic Acid is a current standard of care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B9E-US-S337 | OTHER | Eli Lilly and Company | None |